Guy has a wealth of business management and execution experience with a track record of fundraising for medical start-ups. As its first CEO, he was extensively involved in the establishment of PhenUtest. Prior to this was as CEO of a subsidiary of private healthcare provider HCA.
Guy has a degree in law from the University of Oxford, and worked in corporate finance following qualification as a solicitor.
Experienced in business planning and delivery, Will has been involved in PhenUtest since its inception working initially as Chief Operating Officer.
Previously CEO of a consumer product company, he read Natural Sciences at Bath University and began his career as a management consultant for Accenture. He is also COO of retractable syringe company LOM Medical.
Jacinta is an experienced CFO who specialises in working with SMEs. With a focus on providing strategic financial advice to growing companies, as well as developing long-term market and cash flow forecasts. She has worked across multiple industries from financial services to venture capital to healthcare.
PhenUtest is built on Srijan’s research and he is co-inventor of PhenUtest’s foundational intellectual property. He leads the company’s R&D microbiology and core science.
Following an undergraduate degree at the Indian Institute of Technology, Srijan completed a PhD under the supervision of Professor Douglas Kell at the University of Manchester. He then undertook post-doctoral research at the University of Liverpool.
David is a successful medical device engineer with over twenty years’ of experience. He has been involved in the development of the first fully portable PCR and the first PCR-based point-of-care test for the infectious diseases chlamydia and gonorrhea to gain US FDA clearance.
David has also worked on the development and scale-up of a range of other diagnostic projects in the UK and Europe. He has a First Class Medical Engineering degree.
David has significant experience in the development and regulation of in vitro diagnostics.
He has worked in the industry for almost two decades, primarily with binx health, where he was involved in the development and regulatory approval of the first PCR-based point-of-care test for chlamydia and gonorrhea to gain both FDA clearance and CLIA waiver.
David has a degree in Microbiology and German, a PhD in Molecular Microbiology from the University of Manchester and undertook postdoctoral training at the University of Texas at Austin.
Scientific Advisor Doug Kell is a Professor of Systems Biology at the University of Liverpool and co-inventor of PhenUtest’s underpinning IP.
After an MA and DPhil in Biochemistry at the University of Oxford, he worked at the University of Aberystwyth where he was a Founding Director of Aber Instruments Ltd (Queen’s Award for Export Achievement 1998). He has also led research at the University of Manchester and was CEO of the Biotechnology and Biological Sciences Research Council (2008-2013).